ESMO Immuno Oncology 2021 English Archives

Established and novel chemo-free combinations in immuno-oncology

Immunotherapy was the major breakthrough in the treatment of lung cancer in the past years. The PD-1 inhibitor pembrolizumab is approved for the treatment of various tumor entities including advanced or metastatic non-small cell lung cancer (a/mNSCLC). Lenvatinib, a multikinase inhibitor and antineoplastic agent that is so far approved for certain solid tumors but not NSCLC, already showed promising antitumoral effects and a manageable safety profile when combined with pembrolizumab in a phase I/II trial.

Immune checkpoint blockade combined with chemotherapy in solid tumors

Non-small cell lung cancer (NSCLC) is a severe disease with poor outcomes since the majority of patients present with stage IV disease at diagnosis. Approved treatment options in the first-line setting of advanced NSCLC (aNSCLC) with wildtype EGFR/ALK include bevacizumab - a VEGF targeting monoclonal antibody - and PD-1/PD-L1 inhibitors in combination with chemotherapy.

Preface

The ESMO Immuno-Oncology Congress 2021 took place as a hybrid event either in Geneva or online from 8th to 11th December 2021. Compared with the annual ESMO scientific congress, this meeting focused exclusively on the most exciting new data in the promising field of immuno-oncology. In total, 1,124 participants from 67 countries attended one of the 31 on-demand sessions featuring over 193 abstracts, 178 e-posters, 146 presentations and 20 educational sessions.

Oncology

Hematology

Solid Tumors

Hematologic Malignancies

Collaborations

Supporter

SPONSORS